A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Therapeutic Advances in Childhood Leukemia Consortium
Stanford University
University of Nebraska
Washington University School of Medicine
University of Nebraska
University of Nebraska
Albert Einstein College of Medicine
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Northwestern University
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Mayo Clinic
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
University of Washington
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
University of Miami
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Massachusetts General Hospital
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Mayo Clinic
Alliance for Clinical Trials in Oncology
Columbia University